Tabula Rasa HealthCare, Inc. (TRHC) acquires Personica, LLC and its subsidiaries PersonifilRx, Pharmastar and PersonifilRx New England, a provider of pharmacy services, including 340B and Medicare Part D administration solutions to Programs of All-inclusive Care for the Elderly.
Fulcrum Therapeutics, Inc. (FULC) announced that the Investigational New Drug application is now in effect for its Phase 1 trial in healthy adult volunteers with FTX-6058 for sickle cell disease. FTX-6058 is a small molecule designed to increase expression of fetal hemoglobin with the potential to treat hemoglobinopathies such as sickle cell disease and beta-thalassemia.
Apellis Pharmaceuticals, Inc. (APLS) initiated registrational programs of pegcetacoplan, a targeted C3 therapy, for people living with C3 glomerulopathy or immune complex membranoproliferative glomerulonephritis (IC-MPGN), rare diseases that can lead to kidney failure within five to 10 years, and amyotrophic lateral sclerosis, a devastating neurodegenerative disease that leads to progressive muscle weakness and paralysis. Uncontrolled activation of the complement cascade, a part of the body's immune system, is believed to play a role in the progression of these serious diseases.
Intercontinental Exchange, Inc. (ICE) announces that ICE Benchmark Administration Limited has launched an initial, "Beta", version of its GBP ICE Swap Rate for SONIA swaps.
Zai Lab Limited (ZLAB) dosed the first patient in China in the global Phase 3 POD1UM-304 study evaluating retifanlimab, an investigational anti-PD-1 antibody, in combination with platinum-based chemotherapy in patients with first-line metastatic non-small-cell lung cancer.
News 
Market Data 
Discover 
